Kinarus Therapeutics : June 2022 Investor Presentation

Corporate Presentation

June 2022

Disclaimer

This presentation is not and under no circumstances shall be construed as a solicitation, offer, or recommendation, to buy or sell securities issued by Kinarus Therapeutics Holding AG or any shares in Kinarus AG (together "Kinarus"). Kinarus makes no representation (either express or implied) that information and opinions expressed in this presentation are accurate, complete or up to date. Kinarus disclaims, without limitation, all liability for any loss or damage of any kind, including any direct, indirect or consequential damages, which might be incurred in connection with the information contained in this presentation.

This presentation expressly or implicitly contains certain forward-looking statements concerning Kinarus Therapeutics Holding AG, Kinarus AG and their business. Certain of these forward-looking statements can be identified by the use of forward-looking terminology or by discussions of strategy, plans or intentions. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Kinarus Therapeutics Holding AG and Kinarus AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. There can be no guarantee that any of the research and/or development projects described will succeed or that any news products or indications will be brought to market. Similarly, there can be no guarantee that Kinarus Therapeutics Holding AG, Kinarus AG or any future product or indication will achieve any particular level of revenue. In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products, including, without limitation: unexpected preclinical and clinical trial results; unexpected regulatory actions or delays or government regulation generally; Kinarus Therapeutics Holding AG's or Kinarus AG's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing and other political pressures. Kinarus Therapeutics Holding AG is providing the information in this presentation as of the date of the publication and does not undertake any obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

2

Overview

• Kinarus Therapeutics Holding AG
• • Headquarters: Basel, Switzerland
  • Six Swiss Exchange: KNRS
  • Shares outstanding: 1.07 BN
  • Cash: CHF8.8 M*
  • Debt: CHF7.8 M*
  • Market cap: CHF36.4 M
  • Avg daily trading volume: 4.2 M
• Major Shareholders
• • Management & Board: 20.3%
  • Public free float: 52.4%

*as of 31 Dec 2021

• Phase 2 asset: KIN001
• • New drug combination
  • • Pamapimod in-licensed from Roche (Phase 2)
    • Pioglitazone (marketed generic)
    • Combo is synergistic & addresses issues
  • Indications for value creation
  • • AMD
    • IPF
    • Covid-19
• Strategy
• • In-licenseclinical-stagedrug-candidates
  • Develop to proof of concept
  • Exit

3

Experienced Leadership

We are drug developers

Dr. Alexander Bausch							Subhasis Roy
Chief Executive Officer							Interim CFO
		Dr. Matthew Wright				Claudia Berger
		Chief Operations Officer				Chief Clinical Dev. Officer
		Head of Research
				Dr. Thierry Fumeaux
				Chief Medical Officer

• Direct know-how and in-depth expertise with Kinarus' therapeutic targets and disease indications
• Established relationships with leading experts in clinical development

4

Scientific and Clinical Advisors

Dr. Viktor Boerlin

Chief Medical Advisor

Age-Related Macular Degeneration (AMD)

Prof. Dr. Hendrik Scholl	Prof. Dr. Christian Prünte
Director, Institute of Molecular and Clinical
Ophthalmology Basel (IOB)	Head of Clinical Trials Platform
Professor and Chairman of the Department	Institute of Molecular and Clinical
Ophthalmology Basel (IOB)
of Ophthalmology, University of Basel,
Switzerland	Clinical Head Physician
Chair of the European Vision Institute EEIG,
University Hospital Basel
the European Alliance for the Promotion of
Vision Research and Ophthalmology

Dr. Bianca Gerendas

Managing Director

Vienna Read Center, Vienna, Austria

Associate Director,

Christian Doppler Laboratory

of Ophthalmic Image Analysis

Idiopathic Pulmonary Fibrosis (IPF)

Katrin Hostettler MD, PhD

Head of Dept., Pulmonology

University Hospital Basel

5